Literature DB >> 30308779

The prevalence of neuroleptic malignant syndrome in learning disability.

Caryl N Morgan1, Renarta Rowe2.   

Abstract

OBJECTIVES: No information has been published on the incidence of neuroleptic malignant syndrome in learning disability. However, some studies of individuals who have developed neuroleptic malignant syndrome have suggested that individuals with learning disabilities may be over represented. This study aims to identify the association between learning disability and neuroleptic malignant syndrome.
METHOD: A retrospective case-note analysis was performed with psychiatric case notes for clients with learning disability, in two geographical catchment areas. It was recorded whether clients had been exposed to neuroleptics, and whether any neurological symptoms had subsequently developed which could have been suggestive of neuroleptic malignant syndrome.
RESULTS: It was found that 301 individuals had been exposed to neuroleptics, out of 570 case notes examined. Only one case of neuroleptic malignant syndrome was identified, giving a lifetime prevalence rate of 0.3%.
CONCLUSION: This study failed to demonstrate a higher than expected prevalence of neuroleptic malignant syndrome in clients with learning disability exposed to neuroleptics.

Entities:  

Year:  2003        PMID: 30308779     DOI: 10.1017/S0790966700007801

Source DB:  PubMed          Journal:  Ir J Psychol Med        ISSN: 0790-9667


  1 in total

1.  Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report.

Authors:  Francesco Piacenza; Suet Kee Ong; Patrick O'Brien; Maurice Clancy
Journal:  Clin Case Rep       Date:  2021-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.